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Table 1
Response
deﬁnition
Sensitivity Speciﬁcity Average
Day 28 CR 48% 81% 65%
CR+VGPR 82% 66% 74%
Day 56 CR 64% 82% 73%
CR+VGPR 83% 74% 78%
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autoimmunity (GVA), on the other hand, is suggested from
the fact that autoimmune diseases are ameliorated by allo-
geneic transplantation for accompanying hematologic
disorder. GVHD can be thought as a typical autoimmune
disease caused by donor T cells. From an experience of the
autologous (recipient cells) transplantation for severe GVHD,
which resulted in successful control of GVHD, but disease
relapse probably due to cancelling the GVL effect, we have
pursued the possibility of rescue transplantation from
another donor for refractory acute GVHD in a murine model
and in a clinical trial.
Methods: In a murine GVHD model of BDF1 (H-2b/d) to
B6C3F1 (H-2b/k), GVHD mice underwent a second BMT from
B6B10F1 (H-2b/s) following low-dose TBI 2-3 weeks after ﬁrst
BMT. In a clinical trial, 16 patients who developed severe
acute GVHD, refractory to three to ﬁve lines of GVHD-speciﬁc
treatments, underwent allogeneic stem cell transplantation
using reduced-intensity conditioning regimens with grafts
from a second donor.
Results: In the murine model, GVHD could be successfully
treated by a second BMT. For successful treatment of GVHD,
rapid achievement of full second-donor chimerism was
required. The mice were relatively resistant to new devel-
opment of GVHD by second-donor grafts. The timing of the
second BMT, the intensity of conditioning, and donor selec-
tion could be important. In the clinical trial, among 15
transplantations that could be evaluated, rescue donor grafts
were engrafted in 11 cases and rejected in 4 cases. For
patients who achieved rescue donor engraftment, the
response rate was 90% (CR 8, PR 2, stable 1). 6 of 8 patients
with CR survived without GVHD symptoms, with a median
follow-up of 5.8 years. No new development of GVHD by the
second graft was observed. In contrast, no long-term survi-
vors were observed in patients who rejected rescue donor
grafts.
Conclusions: GVHD could be treated by transplantation
using second donor graft, which eliminates ﬁrst donor
lymphocytes in the murine model and the clinical trial. We
would like to propose the concept of Graft-versus-GVHD, on
the analogy of GVA.436
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Background: We evaluated short-term response endpoints
for clinical trials testing initial treatment of acute graft-
versus-host disease (GVHD). We postulated that the deﬁni-
tion of response should include a reduced symptom burden
and improved failure-free survival (FFS), with failure deﬁned
as death, recurrent malignancy or initiation of second-line
systemic treatment. We also postulated that the response
endpoint should include an upper limit of the steroid dose at
the time of assessment.
Methods: In a cohort of 227 adult patients who received
initial systemic steroid treatment for grades IIB-IV acute
GVHD between 2000 and 2005, treatment response was
evaluated at days 28 and 56 after starting treatment. Stan-
dard deﬁnitions were used to deﬁne complete response (CR)
and traditional partial response (PR). Very good partial
response (VGPR) was deﬁned as a subcategory of traditional
PR when patients had minor rash, minor elevations of totalserum bilirubin or minor gastrointestinal symptoms but
otherwise met criteria for CR (2009 Joint Statement, BBMT).
Sensitivity and speciﬁcity analyses were used to evaluate
each response deﬁnition in predicting FFS at 6 months after
initial treatment. Averages of sensitivity and speciﬁcity were
used to evaluate the trade-off between sensitivity and
speciﬁcity.
Results: Response rates were 33% CR, 24% VGPR and 10%
other PR at day 28, and 40% CR, 14% VGPR and 7% other PR at
day 56. Residual symptom burden at days 28 and 56 after
treatment was lower in patients with VGPR than in those
with other PR, indicating that VGPR is preferred over tradi-
tional PR. In evaluating day 28 and day 56 response endpoints
as predictors of FFS at 6 months, loss of sensitivity out-
weighed the gain of speciﬁcity with CR compared to
CR+VGPR (Table 1). Sensitivity for CR+VGPR was similar at
days 28 and 56, but speciﬁcity was higher at day 56 than at
day 28. Since CR+VGPR at day 56 still had a 26% false-positive
rate (i.e., 74% speciﬁcity), we evaluated response deﬁnitions
that incorporated an upper limit of the steroid dose as an
additional criterion of success (Figure 1). As shown by the
averages, sensitivity and speciﬁcity showed a balanced trade-
off at prednisone limits between 2.0 and 0.5 mg/kg/day, but
loss of sensitivity outweighed the gain of speciﬁcity at limits
below0.5mg/kg/day. Incorporation of prednisone doses0.5
mg/kg/day in the CR+VGPR endpoint deﬁnition at day 56
decreased the false-positive rate to 15%. When recurrent
malignancy was excluded from the deﬁnition of failure after
day 56, this endpoint had a false-positive rate of only 4%.
Conclusion: Our results support the use of CR+VGPR with an
upper limit of the steroid dose at day 56 as the short-term
response endpoint for acute GVHD treatment trials.Figure 1.
